Which treatment should patients with high-risk T1G3 bladder cancer receive?
George J Huang* and John P Stein
Correspondence *Keck School of Medicine, Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
Email georgejh@usc.edu
This article has no abstract so we have provided the first paragraph of the full text.
The management of T1G3 bladder cancer is one of the most difficult clinical challenges faced by urologists. Unfortunately, no clinical trials to date have compared long-term results from patients who undergo immediate or early cystectomy with results from patients who receive initial conservative management with intravesical BCG after transurethral resection, and proceed to cystectomy only in the event of clear progression to muscle involvement (T2). This thoughtful study pools together currently available data from published literature and expert opinion (with their respective limitations and flaws), employing a Markov model to estimate the LE and QALE for patients who undergo one of the two treatments.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.